About
This forum is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice.
The programmes are free from commercial bias, and feature leading experts sharing their knowledge and experience in the form of video tutorials.
Podcasts
AxSpA Podcast: Tofacitinib, Golimumab, and Fatigue
Publications
Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis
Publications
Cardiovascular Safety of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: Systematic Review and Network Meta-analysis
Publications
Differences and Similarities Between the EULAR/ASAS-EULAR and National Recommendations for Treatment of Patients with Psoriatic Arthritis and Axial Spondyloarthritis Across Europe
Publications
Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial
Publications
Long-Term Safety and Efficacy of Ixekizumab in Patients with Axial Spondyloarthritis: 3-year Data from the COAST Program
Publications
The Risk and Predictors of Malignancies in Ankylosing Spondylitis Patients in Israel—A Retrospective Electronic Data-Based Study
Publications
Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
Podcasts
Discussing Rheumatology: July 2023
Publications
Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
Publications
Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients with Rheumatoid Arthritis Receiving Tofacitinib
Podcasts
Discussing PsA: Secukinumab in Oligoarticular PsA & JAK Inhibition-related Malignancies
Podcasts
Author Interview: Laura Coates
Publications
Do Fatty Lesions Explain the Effect of Inflammation on New Syndesmophytes in Patients with Radiographic Axial Spondyloarthritis? Results From the SIAS Cohort and ASSERT Trial
Publications
The 2023 Pipeline of Disease-Modifying Antirheumatic Drugs (DMARDs) in Clinical Development for Spondyloarthritis (including psoriatic arthritis): a Systematic Review of Trials
Podcasts
Author Interview: Mark Russell
Publications
A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
Publications
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 3-year Results from the Open-Label Extension of the Randomised Controlled Phase 3 SELECT-PsA 2 Study
Publications
Comparative Effectiveness of First-Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set
Publications
Mirikizumab as induction and maintenance therapy for ulcerative colitis
Publications
Tofacitinib versus Methotrexate as the First-line Disease-modifying Antirheumatic Drugs in the treatment of Rheumatoid Arthritis: An Open-label Randomized Controlled Trial
Podcasts
Discussing Rheumatology: June 2023
Publications
JAK Inhibitors and the Risk of Malignancy: A Meta-analysis Across Disease Indications
Publications
Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
Publications
Effect of Body Mass Index on Treatment Response of Biologic/ Targeted-Synthetic DMARDs in Patients With Rheumatoid Arthritis, Psoriatic Arthritis or Axial Spondyloarthritis. A Systematic Review
Publications
Sustained low functional impairment in axial spondyloarthritis (axSpA): Which are the primary outcomes that should be targeted to achieve this?
Publications
Effects of Filgotinib on Semen Parameters and Sex Hormones in Male Patients with Inflammatory Diseases: Results from the Phase 2, Randomised, Double-blind, Placebo-controlled MANTA and MANTA-RAy Studies
Publications
Baricitinib Improves Bone Properties and Biomechanics in Patients with Rheumatoid Arthritis – Results of the Prospective Interventional BARE BONE Trial
Publications
Two‑Year Imaging Outcomes from a Phase 3 Randomized Trial of Secukinumab in Patients with Non‑Radiographic Axial Spondyloarthritis
Publications
Improvement in Patient-reported Outcomes and Work Productivity Following 3-year Ustekinumab or Tumour Necrosis Factor Inhibitor Treatment in Patients with Psoriatic Arthritis: Results from the PsABio Real-world Study
Publications
Pain and Inflammation as Mediators of Tofacitinib Treatment Effect on Fatigue in Patients with Ankylosing Spondylitis: A Mediation Analysis
Publications